Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) is a publicly traded Healthcare sector company. As of May 21, 2026, EPRX trades at $6.66 with a market cap of $437.04M and a P/E ratio of 0.00. EPRX moved +1.27% today. Year to date, EPRX is -17.06%; over the trailing twelve months it is +63.34%. Its 52-week range spans $2.20 to $9.32. Analyst consensus is strong buy with an average price target of $14.80. Rallies surfaces EPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Eupraxia Achieves >90% Inflammation, >83% Fibrosis Improvement at Top Dose: RESOLVE trial EoEHSS sub scores for inflammation improved across all cohorts at 12 and 36 weeks, with the highest dose (20×8mg) yielding over 90% reductions in inflammation grade and stage and over 83% improvements in fibrosis. Architectural sub scores also improved across most cohorts at both time points.
| Metric | Value |
|---|---|
| Price | $6.66 |
| Market Cap | $437.04M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.32 |
| 52-Week Low | $2.20 |
| Volume | 23 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
6 analysts cover EPRX: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.80.